Search Results - "PAWLIK, C. A"

  • Showing 1 - 8 results of 8
Refine Results
  1. 1

    Comparison of Activation of CPT-11 by Rabbit and Human Carboxylesterases for Use in Enzyme/Prodrug Therapy by DANKS, M. K, MORTON, C. L, KRULL, E. J, CHESHIRE, P. J, RICHMOND, L. B, NAEVE, C. W, PAWLIK, C. A, HOUGHTON, P. J, POTTER, P. M

    Published in Clinical cancer research (01-04-1999)
    “…Several recent studies have examined the possibility of producing tumor-specific cytotoxicity with various enzyme/prodrug combinations. The enzymes are…”
    Get full text
    Journal Article
  2. 2

    Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11) by POTTER, P. M, PAWLIK, C. A, MORTON, C. L, NAEVE, C. W, DANKS, M. K

    Published in Cancer research (Chicago, Ill.) (15-06-1998)
    “…We have isolated a cDNA encoding a rabbit carboxylesterase (CE; EC 3.1.1.1) that converts the camptothecin-derived prodrug irinotecan (CPT-11) to the potent…”
    Get full text
    Journal Article
  3. 3

    Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11 by DANKS, M. K, MORTON, C. L, PAWLIK, C. A, POTTER, P. M

    Published in Cancer research (Chicago, Ill.) (1998)
    “…CPT-11 [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin ] is a prodrug that is converted to the active metabolite SN-38 by carboxylesterases…”
    Get full text
    Journal Article
  4. 4

    Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays by PAWLIK, C. A, HOUGHTON, P. J, STEWART, C. F, CHESHIRE, P. J, RICHMOND, L. B, DANKS, M. K

    Published in Clinical cancer research (01-08-1998)
    “…The camptothecin derivative topotecan has been postulated to mediate its antitumor effect through a drug-induced increase in covalent topoisomerase I-DNA…”
    Get full text
    Journal Article
  5. 5

    Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure by DANKS, M. K, PAWLIK, C. A, WHIPPLE, D. O, WOLVERTON, J. S

    Published in Clinical cancer research (01-10-1997)
    “…Camptothecin analogues such as topotecan increase the number of covalent topoisomerase I-DNA complexes, which, in turn, have been proposed to initiate…”
    Get full text
    Journal Article
  6. 6

    Use of a modified ornithine decarboxylase promoter to achieve efficient c-MYC- or N-MYC-regulated protein expression by IYENGAR, Rekha V, PAWLIK, Cynthia A, KRULL, Erik J, PHELPS, Doris A, BURGER, Rebecca A, HARRIS, Linda C, POTTER, Philip M, DANKS, Marv K

    Published in Cancer research (Chicago, Ill.) (01-04-2001)
    “…One of the advantages of viral-directed enzyme prodrug therapy (VDEPT) is its potential for tumor-specific cytotoxicity. However, the viruses used to deliver…”
    Get full text
    Journal Article
  7. 7

    Use of the Ornithine Decarboxylase Promoter to Achieve N-MYC-Mediated Overexpression of a Rabbit Carboxylesterase to Sensitize Neuroblastoma Cells to CPT-11 by Pawlik, C A, Iyengar, R V, Krull, E J, Mason, S E, Khanna, R, Harris, L C, Potter, P M, Danks, M K, Guichard, S M

    Published in Molecular therapy (01-05-2000)
    “…Overexpression of specific transcription factors by tumor cells can be exploited to regulate expression of proteins that induce apoptosis or activate prodrugs,…”
    Get full text
    Journal Article
  8. 8

    Cellular resistance against the novel hybrid anthracycline N-(2-chloroethyl)-N-nitrosoureidodaunorubicin (AD 312) is mediated by combined altered topoisomerase II and O6-methylguanine-DNA methyltransferase activities by Pawlik, C A, Israel, M, Sweatman, T W, Lothstein, L

    Published in Oncology research (1998)
    “…N-(2-Chloroethyl)-N-nitrosoureidodaunorubicin (AD 312), a novel semisynthetic compound with combined anthracycline and nitrosourea alkylating functionalities,…”
    Get more information
    Journal Article